Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - JOUR
LB  - 1.
AU  - Tandogdu, Z
AU  - Lewis, R
AU  - Duncan, A
AU  - Penegar, S
AU  - McDonald, A
AU  - Vale, L
TI  - Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness
J2  - BMJ Open
PY  - 2019
VL  - 9
SP  - e022268
UR  - https://doi.org/10.1136/bmjopen-2018-022268
ER  - 
TY  - ELEC
LB  - 2.
AU  - Cancer Research UK
TI  - Bladder Cancer Statistics
PY  - 2020
UR  - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer
M1  - June 2021
ER  - 
TY  - JOUR
LB  - 3.
AU  - Aveyard, P
AU  - Adab, P
AU  - Cheng, KK
AU  - Wallace, DM
AU  - Hey, K
AU  - Murphy, MF
TI  - Does smoking status influence the prognosis of bladder cancer? A systematic review
J2  - BJU Int
PY  - 2002
VL  - 90
SP  - 228
EP  - 239
UR  - https://doi.org/10.1046/j.1464-410X.2002.02880.x
ER  - 
TY  - JOUR
LB  - 4.
AU  - Puente, D
AU  - Hartge, P
AU  - Greiser, E
AU  - Cantor, KP
AU  - King, WD
AU  - González, CA
TI  - A pooled analysis of bladder cancer case-control studies evaluating smoking in men and women
J2  - Cancer Causes Control
PY  - 2006
VL  - 17
SP  - 71
EP  - 79
UR  - https://doi.org/10.1007/s10552-005-0389-0
ER  - 
TY  - JOUR
LB  - 5.
AU  - Mistry, M
AU  - Parkin, DM
AU  - Ahmad, AS
AU  - Sasieni, P
TI  - Cancer incidence in the United Kingdom: projections to the year 2030
J2  - Br J Cancer
PY  - 2011
VL  - 105
SP  - 1795
EP  - 1803
UR  - https://doi.org/10.1038/bjc.2011.430
ER  - 
TY  - JOUR
LB  - 6.
AU  - Epstein, JI
AU  - Amin, MB
AU  - Reuter, VR
AU  - Mostofi, FK
TI  - The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee
J2  - Am J Surg Pathol
PY  - 1998
VL  - 22
SP  - 1435
EP  - 1448
UR  - https://doi.org/10.1097/00000478-199812000-00001
ER  - 
TY  - JOUR
LB  - 7.
AU  - Edwards, TJ
AU  - Dickinson, AJ
AU  - Natale, S
AU  - Gosling, J
AU  - McGrath, JS
TI  - A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic
J2  - BJU Int
PY  - 2006
VL  - 97
SP  - 301
EP  - 305
UR  - https://doi.org/10.1111/j.1464-410X.2006.05976.x
ER  - 
TY  - JOUR
LB  - 8.
AU  - Khadra, MH
AU  - Pickard, RS
AU  - Charlton, M
AU  - Powell, PH
AU  - Neal, DE
TI  - A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice
J2  - J Urol
PY  - 2000
VL  - 163
SP  - 524
EP  - 527
UR  - https://doi.org/10.1016/S0022-5347(05)67916-5
ER  - 
TY  - JOUR
LB  - 9.
AU  - Bryan, RT
AU  - Collins, SI
AU  - Daykin, MC
AU  - Zeegers, MP
AU  - Cheng, KK
AU  - Wallace, DM
AU  - Sole, GM
TI  - Mechanisms of recurrence of Ta/T1 bladder cancer
J2  - Ann R Coll Surg Engl
PY  - 2010
VL  - 92
SP  - 519
EP  - 524
UR  - https://doi.org/10.1308/003588410X12664192076935
ER  - 
TY  - JOUR
LB  - 10.
AU  - Brausi, M
AU  - Collette, L
AU  - Kurth, K
AU  - van der Meijden, AP
AU  - Oosterlinck, W
AU  - Witjes, JA
TI  - Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies
J2  - Eur Urol
PY  - 2002
VL  - 41
SP  - 523
EP  - 531
UR  - https://doi.org/10.1016/S0302-2838(02)00068-4
ER  - 
TY  - JOUR
LB  - 11.
AU  - Mowatt, G
AU  - N’Dow, J
AU  - Vale, L
AU  - Nabi, G
AU  - Boachie, C
AU  - Cook, JA
TI  - Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis
J2  - Int J Technol Assess Health Care
PY  - 2011
VL  - 27
SP  - 3
EP  - 10
UR  - https://doi.org/10.1017/S0266462310001364
ER  - 
TY  - ELEC
LB  - 12.
AU  - European Association of Urology
TI  - Non-muscle-invasive Bladder Cancer
PY  - 2021
UR  - https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
M1  - June 2021
ER  - 
TY  - JOUR
LB  - 13.
AU  - Sylvester, RJ
AU  - Oosterlinck, W
AU  - van der Meijden, APM
TI  - A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials
J2  - J Urol
PY  - 2004
VL  - 171
SP  - 2186
EP  - 2190
UR  - https://doi.org/10.1097/01.ju.0000125486.92260.b2
ER  - 
TY  - JOUR
LB  - 14.
AU  - Sylvester, RJ
AU  - Oosterlinck, W
AU  - Witjes, JA
TI  - The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials
J2  - Eur Urol
PY  - 2008
VL  - 53
SP  - 709
EP  - 719
UR  - https://doi.org/10.1016/j.eururo.2008.01.015
ER  - 
TY  - JOUR
LB  - 15.
AU  - Sylvester, RJ
AU  - van der Meijden, AP
AU  - Lamm, DL
TI  - Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials
J2  - J Urol
PY  - 2002
VL  - 168
SP  - 1964
EP  - 1970
UR  - https://doi.org/10.1097/01.ju.0000034450.80198.1c
ER  - 
TY  - JOUR
LB  - 16.
AU  - Böhle, A
AU  - Jocham, D
AU  - Bock, PR
TI  - Intravesical bacillus Calmette–Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity
J2  - J Urol
PY  - 2003
VL  - 169
SP  - 90
EP  - 95
UR  - https://doi.org/10.1097/01.ju.0000039680.90768.b3
ER  - 
TY  - JOUR
LB  - 17.
AU  - Shelley, MD
AU  - Court, JB
AU  - Kynaston, H
AU  - Wilt, TJ
AU  - Fish, RG
AU  - Mason, M
TI  - Intravesical bacillus Calmette–Guerin in Ta and T1 bladder cancer
J2  - Cochrane Database Syst Rev
PY  - 2000
VL  - 4
UR  - https://doi.org/10.1002/14651858.CD001986
ER  - 
TY  - GEN
LB  - 18.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Bladder Cancer: Diagnosis and Management
CY  - London
PB  - NICE
PY  - 2015
UR  - www.nice.org.uk/guidance/ng2
Y2  - 11 June 2021
ER  - 
TY  - JOUR
LB  - 19.
AU  - Mariappan, P
AU  - Smith, G
TI  - A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database
J2  - J Urol
PY  - 2005
VL  - 173
SP  - 1108
EP  - 1111
UR  - https://doi.org/10.1097/01.ju.0000149163.08521.69
ER  - 
TY  - JOUR
LB  - 20.
AU  - Sangar, VK
AU  - Ragavan, N
AU  - Matanhelia, SS
AU  - Watson, MW
AU  - Blades, RA
TI  - The economic consequences of prostate and bladder cancer in the UK
J2  - BJU Int
PY  - 2005
VL  - 95
SP  - 59
EP  - 63
UR  - https://doi.org/10.1111/j.1464-410X.2005.05249.x
ER  - 
TY  - JOUR
LB  - 21.
AU  - Leal, J
AU  - Luengo-Fernandez, R
AU  - Sullivan, R
AU  - Witjes, JA
TI  - Economic burden of bladder cancer across the European Union
J2  - Eur Urol
PY  - 2016
VL  - 69
SP  - 438
EP  - 447
UR  - https://doi.org/10.1016/j.eururo.2015.10.024
ER  - 
TY  - JOUR
LB  - 22.
AU  - Porter, MP
AU  - Penson, DF
TI  - Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature
J2  - J Urol
PY  - 2005
VL  - 173
SP  - 1318
EP  - 1322
UR  - https://doi.org/10.1097/01.ju.0000149080.82697.65
ER  - 
TY  - JOUR
LB  - 23.
AU  - Tan, WS
AU  - Teo, CH
AU  - Chan, D
AU  - Ang, KM
AU  - Heinrich, M
AU  - Feber, A
TI  - Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed-methods approach
J2  - BJU Int
PY  - 2020
VL  - 125
SP  - 669
EP  - 678
UR  - https://doi.org/10.1111/bju.15008
ER  - 
TY  - JOUR
LB  - 24.
AU  - Yoshimura, K
AU  - Utsunomiya, N
AU  - Ichioka, K
AU  - Matsui, Y
AU  - Terai, A
AU  - Arai, Y
TI  - Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey
J2  - Urology
PY  - 2005
VL  - 65
SP  - 290
EP  - 294
UR  - https://doi.org/10.1016/j.urology.2004.09.050
ER  - 
TY  - JOUR
LB  - 25.
AU  - Zaak, D
AU  - Karl, A
AU  - Knüchel, R
AU  - Stepp, H
AU  - Hartmann, A
AU  - Reich, O
TI  - Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy
J2  - BJU Int
PY  - 2005
VL  - 96
SP  - 217
EP  - 222
UR  - https://doi.org/10.1111/j.1464-410X.2005.05604.x
ER  - 
TY  - JOUR
LB  - 26.
AU  - Marti, A
AU  - Jichlinski, P
AU  - Lange, N
AU  - Ballini, JP
AU  - Guillou, L
AU  - Leisinger, HJ
TI  - Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer
J2  - J Urol
PY  - 2003
VL  - 170
SP  - 428
EP  - 432
UR  - https://doi.org/10.1097/01.ju.0000075054.38441.2d
ER  - 
TY  - JOUR
LB  - 27.
AU  - Mowatt, G
AU  - Zhu, S
AU  - Kilonzo, M
AU  - Boachie, C
AU  - Fraser, C
AU  - Griffiths, TR
TI  - Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer
J2  - Health Technol Assess
PY  - 2010
VL  - 14
IS  - 4
UR  - https://doi.org/10.3310/hta14040
ER  - 
TY  - JOUR
LB  - 28.
AU  - Stenzl, A
AU  - Penkoff, H
AU  - Dajc-Sommerer, E
AU  - Zumbraegel, A
AU  - Hoeltl, L
AU  - Scholz, M
TI  - Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial
J2  - Cancer
PY  - 2011
VL  - 117
SP  - 938
EP  - 947
UR  - https://doi.org/10.1002/cncr.25523
ER  - 
TY  - JOUR
LB  - 29.
AU  - Stenzl, A
AU  - Burger, M
AU  - Fradet, Y
AU  - Mynderse, LA
AU  - Soloway, MS
AU  - Witjes, JA
TI  - Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer
J2  - J Urol
PY  - 2010
VL  - 184
SP  - 1907
EP  - 1913
UR  - https://doi.org/10.1016/j.juro.2010.06.148
ER  - 
TY  - JOUR
LB  - 30.
AU  - Grossman, HB
AU  - Stenzl, A
AU  - Fradet, Y
AU  - Mynderse, LA
AU  - Kriegmair, M
AU  - Witjes, JA
TI  - Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy
J2  - J Urol
PY  - 2012
VL  - 188
SP  - 58
EP  - 62
UR  - https://doi.org/10.1016/j.juro.2012.03.007
ER  - 
TY  - JOUR
LB  - 31.
AU  - Dindo, D
AU  - Demartines, N
AU  - Clavien, PA
TI  - Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey
J2  - Ann Surg
PY  - 2004
VL  - 240
SP  - 205
EP  - 213
UR  - https://doi.org/10.1097/01.sla.0000133083.54934.ae
ER  - 
TY  - GEN
LB  - 32.
AU  - National Cancer Institute
TI  - CTCAEs v4: Common Terminology Criteria for Adverse Events (CTCAE)
CY  - Rockville, MD
PB  - National Cancer Institute
PY  - 2010
UR  - http://ctep.cancer.gov/
Y2  - 12 February 2021
ER  - 
TY  - JOUR
LB  - 33.
AU  - Fine, JP
AU  - Gray, RJ
TI  - A proportional hazards model for the subdistribution of a competing risk
J2  - J Am Stat Assoc
PY  - 1999
VL  - 94
SP  - 496
EP  - 509
UR  - https://doi.org/10.1080/01621459.1999.10474144
ER  - 
TY  - GEN
LB  - 34.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Guide to the Methods of Technology Appraisal 2013.
CY  - London
PB  - NICE
PY  - 2013
UR  - www.nice.org.uk/process/pmg9
Y2  - June 2021
ER  - 
TY  - JOUR
LB  - 35.
AU  - Barber, JA
AU  - Thompson, SG
TI  - Analysis of cost data in randomized trials: an application of the non-parametric bootstrap
J2  - Stat Med
PY  - 2000
VL  - 19
SP  - 3219
EP  - 3236
UR  - https://doi.org/10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P
ER  - 
TY  - GEN
LB  - 36.
AU  - Joint Formulary Committee
TI  - British National Formulary
ET  - 76th
CY  - London
PB  - BMJ Group and Pharmaceutical Press
PY  - 2018
ER  - 
TY  - GEN
LB  - 37.
AU  - NHS Improvement
TI  - NHS Reference Costs 2018–19
CY  - London
PB  - NHS Improvement
PY  - 2019
ER  - 
TY  - BOOK
LB  - 38.
AU  - Curtis, L
AU  - Burns, A
TI  - Unit Costs of Health and Social Care
CY  - Canterbury
PB  - PSSRU, University of Kent
PY  - 2018
ER  - 
TY  - ELEC
LB  - 39.
AU  - International Monetary Fund
TI  - World Economic Outlook Database (October 2018)
UR  - www.imf.org/external/pubs/ft/weo/2019/01/weodata/index.aspx
M1  - 23 April 2019
ER  - 
TY  - GEN
LB  - 40.
AU  - Department of Transport
TI  - Transport Analysis Guidance (TAG) Data Book v1.13. 1
CY  - London
PB  - Department for Transport
PY  - 2020
UR  - www.gov.uk/government/publications/tag-data-book
Y2  - June 2021
ER  - 
TY  - JOUR
LB  - 41.
AU  - Dolan, P
TI  - Modeling valuations for EuroQol health states
J2  - Med Care
PY  - 1997
VL  - 35
SP  - 1095
EP  - 1108
UR  - https://doi.org/10.1097/00005650-199711000-00002
ER  - 
TY  - JOUR
LB  - 42.
AU  - White, IR
AU  - Horton, NJ
AU  - Carpenter, J
AU  - Pocock, SJ
TI  - Strategy for intention to treat analysis in randomised trials with missing outcome data
J2  - BMJ
PY  - 2011
VL  - 342
SP  - d40
UR  - https://doi.org/10.1136/bmj.d40
ER  - 
TY  - BOOK
LB  - 43.
AU  - Rubin, DB
TI  - Multiple Imputation for Nonresponse in Surveys
CY  - Chichester
PB  - John Wiley & Sons
PY  - 2004
ER  - 
TY  - BOOK
LB  - 44.
AU  - Greene, WH
TI  - Econometric Analysis: Global Edition
CY  - London
PB  - Pearson Education UK
PY  - 2014
ER  - 
TY  - JOUR
LB  - 45.
AU  - Briggs, AH
AU  - Wonderling, DE
AU  - Mooney, CZ
TI  - Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation
J2  - Health Econ
PY  - 1997
VL  - 6
SP  - 327
EP  - 340
UR  - https://doi.org/10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W
ER  - 
TY  - JOUR
LB  - 46.
AU  - Briggs, AH
AU  - Gray, AM
TI  - Handling uncertainty when performing economic evaluation of healthcare interventions
J2  - Health Technol Assess
PY  - 1999
VL  - 3
IS  - 2
UR  - https://doi.org/10.3310/hta3020
ER  - 
TY  - JOUR
LB  - 47.
AU  - Briggs, AH
AU  - O’Brien, BJ
AU  - Blackhouse, G
TI  - Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies
J2  - Annu Rev Public Health
PY  - 2002
VL  - 23
SP  - 377
EP  - 401
UR  - https://doi.org/10.1146/annurev.publhealth.23.100901.140534
ER  - 
TY  - GEN
LB  - 48.
AU  - National Research Council
TI  - Principles and Methods of Sensitivity Analyses
A2  - National Research Council (US) Panel on Handling Missing Data in Clinical Trials
TI  - The Prevention and Treatment of Missing Data in Clinical Trials
CY  - Washington, DC
PB  - Academies Press (US)
PY  - 2010
ER  - 
TY  - JOUR
LB  - 49.
AU  - Little, RJ
TI  - Pattern-mixture models for multivariate incomplete data
J2  - J Am Stat Assoc
PY  - 1993
VL  - 88
SP  - 125
EP  - 134
UR  - https://doi.org/10.1080/01621459.1993.10594302
ER  - 
TY  - JOUR
LB  - 50.
AU  - Ratitch, B
AU  - O’Kelly, M
AU  - Tosiello, R
TI  - Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models
J2  - Pharm Stat
PY  - 2013
VL  - 12
SP  - 337
EP  - 347
UR  - https://doi.org/10.1002/pst.1549
ER  - 
TY  - JOUR
LB  - 51.
AU  - Permutt, T
TI  - Sensitivity analysis for missing data in regulatory submissions
J2  - Stat Med
PY  - 2016
VL  - 35
SP  - 2876
EP  - 2879
UR  - https://doi.org/10.1002/sim.6753
ER  - 
TY  - JOUR
LB  - 52.
AU  - Heer, R
AU  - Lewis, R
AU  - Vadiveloo, T
AU  - Yu, G
AU  - Mariappan, P
AU  - Cresswell, J
TI  - Randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer
J2  - NEJM Evid
PY  - 2022
VL  - 1
SP  - 10.
UR  - https://doi.org/10.1056/EVIDoa2200092
ER  - 
TY  - JOUR
LB  - 53.
AU  - Kelly, JD
AU  - Tan, WS
AU  - Porta, N
AU  - Mostafid, H
AU  - Huddart, R
AU  - Protheroe, A
TI  - BOXIT – a randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK/07/004)
J2  - Eur Urol
PY  - 2019
VL  - 75
SP  - 593
EP  - 601
UR  - https://doi.org/10.1016/j.eururo.2018.09.020
ER  - 
TY  - JOUR
LB  - 54.
AU  - Oosterlinck, W
AU  - Kurth, KH
AU  - Schröder, F
AU  - Bultinck, J
AU  - Hammond, B
AU  - Sylvester, R
TI  - A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder
J2  - J Urol
PY  - 1993
VL  - 149
SP  - 749
EP  - 752
UR  - https://doi.org/10.1016/S0022-5347(17)36198-0
ER  - 
TY  - JOUR
LB  - 55.
AU  - Sylvester, RJ
AU  - van der Meijden, AP
AU  - Oosterlinck, W
AU  - Witjes, JA
AU  - Bouffioux, C
AU  - Denis, L
TI  - Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
J2  - Eur Urol
PY  - 2006
VL  - 49
SP  - 466
EP  - 465
UR  - https://doi.org/10.1016/j.eururo.2005.12.031
ER  - 
TY  - JOUR
LB  - 56.
AU  - Mariappan, P
AU  - Lavin, V
AU  - Phua, CQ
AU  - Khan, SAA
AU  - Donat, R
AU  - Smith, G
TI  - Predicting grade and stage at cystoscopy in newly presenting bladder cancers-a prospective double-blind clinical study
J2  - Urology
PY  - 2017
VL  - 109
SP  - 134
EP  - 139
UR  - https://doi.org/10.1016/j.urology.2017.08.007
ER  - 
TY  - JOUR
LB  - 57.
AU  - Mostafid, AH
AU  - Porta, N
AU  - Cresswell, J
AU  - Griffiths, TRL
AU  - Kelly, JD
AU  - Penegar, SR
TI  - CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer
J2  - BJU Int
PY  - 2020
VL  - 125
SP  - 817
EP  - 826
UR  - https://doi.org/10.1111/bju.15038
ER  - 
TY  - JOUR
LB  - 58.
AU  - Soukup, V
AU  - Čapoun, O
AU  - Cohen, D
AU  - Hernández, V
AU  - Burger, M
AU  - Compérat, E
TI  - Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel
J2  - Eur Urol Focus
PY  - 2020
VL  - 6
SP  - 479
EP  - 489
UR  - https://doi.org/10.1016/j.euf.2018.11.005
ER  - 
TY  - JOUR
LB  - 59.
AU  - Chang, SS
AU  - Boorjian, SA
AU  - Chou, R
AU  - Clark, PE
AU  - Daneshmand, S
AU  - Konety, BR
TI  - Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline
J2  - J Urol
PY  - 2016
VL  - 196
SP  - 1021
EP  - 1029
UR  - https://doi.org/10.1016/j.juro.2016.06.049
ER  - 
TY  - JOUR
LB  - 60.
AU  - Babjuk, M
AU  - Burger, M
AU  - Zigeuner, R
AU  - Shariat, SF
AU  - van Rhijn, BW
AU  - Compérat, E
TI  - EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013
J2  - Eur Urol
PY  - 2013
VL  - 64
SP  - 639
EP  - 653
UR  - https://doi.org/10.1016/j.eururo.2013.06.003
ER  - 
TY  - JOUR
LB  - 61.
AU  - Sylvester, RJ
AU  - Rodríguez, O
AU  - Hernández, V
AU  - Turturica, D
AU  - Bauerová, L
AU  - Bruins, HM
TI  - European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: an update from the EAU NMIBC Guidelines Panel
J2  - Eur Urol
PY  - 2021
VL  - 79
SP  - 480
EP  - 488
UR  - https://doi.org/10.1016/j.eururo.2020.12.033
ER  - 
TY  - JOUR
LB  - 62.
AU  - Lammers, RJ
AU  - Palou, J
AU  - Witjes, WP
AU  - Janzing-Pastors, MH
AU  - Caris, CT
AU  - Witjes, JA
TI  - Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy
J2  - BJU Int
PY  - 2014
VL  - 114
SP  - 193
EP  - 201
UR  - https://doi.org/10.1111/bju.12495
ER  - 
TY  - JOUR
LB  - 63.
AU  - Fernandez-Gomez, J
AU  - Madero, R
AU  - Solsona, E
AU  - Unda, M
AU  - Martinez-Piñeiro, L
AU  - Ojea, A
TI  - The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette–Guérin: external validation of the EORTC risk tables
J2  - Eur Urol
PY  - 2011
VL  - 60
SP  - 423
EP  - 430
UR  - https://doi.org/10.1016/j.eururo.2011.05.033
ER  - 
TY  - JOUR
LB  - 64.
AU  - Gravas, S
AU  - Efstathiou, K
AU  - Zachos, I
AU  - Melekos, MD
AU  - Tzortzis, V
TI  - Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride?
J2  - Can J Urol
PY  - 2012
VL  - 19
SP  - 6269
EP  - 6273
ER  - 
TY  - JOUR
LB  - 65.
AU  - Kruck, S
AU  - Bedke, J
AU  - Hennenlotter, J
AU  - Amend, B
AU  - Merseburger, A
AU  - Stenzl, A
AU  - Sievert, KD
TI  - Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics
J2  - Urol Int
PY  - 2011
VL  - 87
SP  - 138
EP  - 142
UR  - https://doi.org/10.1159/000328218
ER  - 
TY  - JOUR
LB  - 66.
AU  - O’Brien, T
AU  - Ray, E
AU  - Chatterton, K
AU  - Khan, MS
AU  - Chandra, A
AU  - Thomas, K
TI  - Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer
J2  - BJU Int
PY  - 2013
VL  - 112
SP  - 1096
EP  - 1104
UR  - https://doi.org/10.1111/bju.12355
ER  - 
TY  - JOUR
LB  - 67.
AU  - Mariappan, P
AU  - Finney, SM
AU  - Head, E
AU  - Somani, BK
AU  - Zachou, A
AU  - Smith, G
TI  - Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking
J2  - BJU Int
PY  - 2012
VL  - 109
SP  - 1666
EP  - 1673
UR  - https://doi.org/10.1111/j.1464-410X.2011.10571.x
ER  - 
TY  - JOUR
LB  - 68.
AU  - Mariappan, P
AU  - Johnston, A
AU  - Padovani, L
AU  - Clark, E
AU  - Trail, M
AU  - Hamid, S
TI  - Enhanced quality and effectiveness of transurethral resection of bladder tumour in non-muscle-invasive bladder cancer: a multicentre real-world experience from Scotland’s Quality Performance Indicators Programme
J2  - Eur Urol
PY  - 2020
VL  - 78
SP  - 520
EP  - 530
UR  - https://doi.org/10.1016/j.eururo.2020.06.051
ER  - 
TY  - JOUR
LB  - 69.
AU  - Kausch, I
AU  - Sommerauer, M
AU  - Montorsi, F
AU  - Stenzl, A
AU  - Jacqmin, D
AU  - Jichlinski, P
TI  - Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies
J2  - Eur Urol
PY  - 2010
VL  - 57
SP  - 595
EP  - 606
UR  - https://doi.org/10.1016/j.eururo.2009.11.041
ER  - 
TY  - JOUR
LB  - 70.
AU  - Rink, M
AU  - Babjuk, M
AU  - Catto, JW
AU  - Jichlinski, P
AU  - Shariat, SF
AU  - Stenzl, A
TI  - Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature
J2  - Eur Urol
PY  - 2013
VL  - 64
SP  - 624
EP  - 638
UR  - https://doi.org/10.1016/j.eururo.2013.07.007
ER  - 
TY  - JOUR
LB  - 71.
AU  - Burger, M
AU  - Grossman, HB
AU  - Droller, M
AU  - Schmidbauer, J
AU  - Hermann, G
AU  - Drăgoescu, O
TI  - Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data
J2  - Eur Urol
PY  - 2013
VL  - 64
SP  - 846
EP  - 854
UR  - https://doi.org/10.1016/j.eururo.2013.03.059
ER  - 
TY  - JOUR
LB  - 72.
AU  - Konecki, T
AU  - Kutwin, P
AU  - Łowicki, R
AU  - Juszczak, AB
AU  - Jabłonowski, Z
TI  - Hexaminolevulinate in the management of nonmuscle invasive bladder cancer: a meta-analysis
J2  - Photobiomodul Photomed Laser Surg
PY  - 2019
VL  - 37
SP  - 551
EP  - 558
UR  - https://doi.org/10.1089/photob.2019.4634
ER  - 
TY  - JOUR
LB  - 73.
AU  - Gallagher, KM
AU  - Gray, K
AU  - Anderson, CH
AU  - Lee, H
AU  - Stewart, S
AU  - Donat, R
AU  - Mariappan, P
TI  - ‘Real-life experience’: recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study
J2  - World J Urol
PY  - 2017
VL  - 35
SP  - 1871
EP  - 1877
UR  - https://doi.org/10.1007/s00345-017-2077-6
ER  - 
TY  - JOUR
LB  - 74.
AU  - Mariappan, P
AU  - Rai, B
AU  - El-Mokadem, I
AU  - Anderson, CH
AU  - Lee, H
AU  - Stewart, S
TI  - Real-life experience: early recurrence with Hexvix® photodynamic diagnosis-assisted transurethral resection of bladder tumour vs good-quality white light TURBT in new non-muscle-invasive bladder cancer
J2  - Urology
PY  - 2015
VL  - 86
SP  - 327
EP  - 331
UR  - https://doi.org/10.1016/j.urology.2015.04.015
ER  - 
TY  - JOUR
LB  - 75.
AU  - Witjes, JA
AU  - Babjuk, M
AU  - Gontero, P
AU  - Jacqmin, D
AU  - Karl, A
AU  - Kruck, S
TI  - Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations
J2  - Eur Urol
PY  - 2014
VL  - 66
SP  - 863
EP  - 871
UR  - https://doi.org/10.1016/j.eururo.2014.06.037
ER  - 
TY  - JOUR
LB  - 76.
AU  - Malmström, PU
AU  - Sylvester, RJ
AU  - Crawford, DE
AU  - Friedrich, M
AU  - Krege, S
AU  - Rintala, E
TI  - An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guérin for non-muscle-invasive bladder cancer
J2  - Eur Urol
PY  - 2009
VL  - 56
SP  - 247
EP  - 256
UR  - https://doi.org/10.1016/j.eururo.2009.04.038
ER  - 
TY  - JOUR
LB  - 77.
AU  - Palou, J
AU  - Hernández, C
AU  - Solsona, E
AU  - Abascal, R
AU  - Burgués, JP
AU  - Rioja, C
TI  - Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study
J2  - BJU Int
PY  - 2015
VL  - 116
SP  - 37
EP  - 43
UR  - https://doi.org/10.1111/bju.13020
ER  - 
TY  - JOUR
LB  - 78.
AU  - Daneshmand, S
AU  - Schuckman, AK
AU  - Bochner, BH
AU  - Cookson, MS
AU  - Downs, TM
AU  - Gomella, LG
TI  - Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
J2  - Nat Rev Urol
PY  - 2014
VL  - 11
SP  - 589
EP  - 596
UR  - https://doi.org/10.1038/nrurol.2014.245
ER  - 
TY  - JOUR
LB  - 79.
AU  - Cabana, MD
AU  - Rand, CS
AU  - Powe, NR
AU  - Wu, AW
TI  - Why don’t physicians follow clinical practice guidelines? A framework for improvement
J2  - JAMA
PY  - 1999
VL  - 282
SP  - 1458
EP  - 1465
UR  - https://doi.org/10.1001/jama.282.15.1458
ER  - 
TY  - JOUR
LB  - 80.
AU  - Sylvester, RJ
AU  - Canfield, SE
AU  - Lam, TB
AU  - Marconi, L
AU  - MacLennan, S
AU  - Yuan, Y
TI  - Conflict of evidence: resolving discrepancies when findings from randomized controlled trials and meta-analyses disagree
J2  - Eur Urol
PY  - 2017
VL  - 71
SP  - 811
EP  - 819
UR  - https://doi.org/10.1016/j.eururo.2016.11.023
ER  - 
TY  - JOUR
LB  - 81.
AU  - Power, NE
AU  - Izawa, J
TI  - Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE)
J2  - Bladder Cancer
PY  - 2016
VL  - 2
SP  - 27
EP  - 36
UR  - https://doi.org/10.3233/BLC-150034
ER  - 
TY  - JOUR
LB  - 82.
AU  - Leiblich, A
AU  - Bryant, RJ
AU  - R McCormick, R
AU  - Crew, J
TI  - The management of non-muscle-invasive bladder cancer: a comparison of European and UK guidelines
J2  - J Clin Urol
PY  - 2018
VL  - 11
SP  - 144
EP  - 148
UR  - https://doi.org/10.1177/2051415818757339
ER  - 
TY  - JOUR
LB  - 83.
AU  - Babjuk, M
AU  - Burger, M
AU  - Compérat, EM
AU  - Gontero, P
AU  - Mostafid, AH
AU  - Palou, J
TI  - European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) – 2019 Update
J2  - Eur Urol
PY  - 2019
VL  - 76
SP  - 639
EP  - 657
UR  - https://doi.org/10.1016/j.eururo.2019.08.016
ER  - 
TY  - JOUR
LB  - 84.
AU  - Hendricksen, K
AU  - Aziz, A
AU  - Bes, P
AU  - Chun, FK
AU  - Dobruch, J
AU  - Kluth, LA
TI  - Discrepancy between European Association of Urology guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey
J2  - Eur Urol Focus
PY  - 2019
VL  - 5
SP  - 681
EP  - 688
UR  - https://doi.org/10.1016/j.euf.2017.09.002
ER  - 
TY  - JOUR
LB  - 85.
AU  - Witjes, JA
AU  - Palou, J
AU  - Soloway, M
AU  - Lamm, D
AU  - Kamat, AM
AU  - Brausi, M
TI  - Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette–Guérin (BCG): results of an international individual patient data survey (IPDS)
J2  - BJU Int
PY  - 2013
VL  - 112
SP  - 742
EP  - 750
UR  - https://doi.org/10.1111/bju.12012
ER  - 
TY  - JOUR
LB  - 86.
AU  - Sylvester, RJ
AU  - Brausi, MA
AU  - Kirkels, WJ
AU  - Hoeltl, W
AU  - Calais Da Silva, F
AU  - Powell, PH
TI  - Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette–Guérin, and bacillus Calmette–Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder
J2  - Eur Urol
PY  - 2010
VL  - 57
SP  - 766
EP  - 773
UR  - https://doi.org/10.1016/j.eururo.2009.12.024
ER  - 
TY  - JOUR
LB  - 87.
AU  - Tapiero, S
AU  - Helfand, A
AU  - Kedar, D
AU  - Yossepowitch, O
AU  - Nadu, A
AU  - Baniel, J
TI  - Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer
J2  - Urology
PY  - 2018
VL  - 118
SP  - 107
EP  - 113
UR  - https://doi.org/10.1016/j.urology.2018.04.039
ER  - 
TY  - JOUR
LB  - 88.
AU  - Brausi, M
AU  - Oddens, J
AU  - Sylvester, R
AU  - Bono, A
AU  - van de Beek, C
AU  - van Andel, G
TI  - Side effects of bacillus Calmette–Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG
J2  - Eur Urol
PY  - 2014
VL  - 65
SP  - 69
EP  - 76
UR  - https://doi.org/10.1016/j.eururo.2013.07.021
ER  - 
TY  - JOUR
LB  - 89.
AU  - Oddens, J
AU  - Brausi, M
AU  - Sylvester, R
AU  - Bono, A
AU  - van de Beek, C
AU  - van Andel, G
TI  - Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette–Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance
J2  - Eur Urol
PY  - 2013
VL  - 63
SP  - 462
EP  - 472
UR  - https://doi.org/10.1016/j.eururo.2012.10.039
ER  - 
TY  - JOUR
LB  - 90.
AU  - van den Bosch, S
AU  - Alfred Witjes, J
TI  - Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review
J2  - Eur Urol
PY  - 2011
VL  - 60
SP  - 493
EP  - 500
UR  - https://doi.org/10.1016/j.eururo.2011.05.045
ER  - 
TY  - JOUR
LB  - 91.
AU  - Chen, C
AU  - Huang, H
AU  - Zhao, Y
AU  - Liu, H
AU  - Luo, Y
AU  - Sylvester, RJ
TI  - Diagnostic accuracy of photodynamic diagnosis with 5-aminolevulinic acid, hexaminolevulinate and narrow band imaging for non-muscle invasive bladder cancer
J2  - J Cancer
PY  - 2020
VL  - 11
SP  - 1082
EP  - 1093
UR  - https://doi.org/10.7150/jca.34527
ER  - 
TY  - JOUR
LB  - 92.
AU  - Chen, C
AU  - Huang, H
AU  - Zhao, Y
AU  - Liu, H
AU  - Sylvester, R
AU  - Lin, T
AU  - Huang, J
TI  - Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis
J2  - BMJ Open
PY  - 2019
VL  - 9
SP  - e028173
UR  - https://doi.org/10.1136/bmjopen-2018-028173
ER  - 
TY  - JOUR
LB  - 93.
AU  - Bolenz, C
AU  - Rother, J
AU  - Meessen, S
AU  - Grychtol, B
AU  - Majlesara, A
AU  - Gharabaghi, N
TI  - The development of real-time multispectral imaging for the diagnostics of bladder cancer
J2  - Urologe A
PY  - 2019
VL  - 58
SP  - 1435
EP  - 1442
UR  - https://doi.org/10.1007/s00120-019-01037-3
ER  - 
TY  - JOUR
LB  - 94.
AU  - Brunckhorst, O
AU  - Ong, QJ
AU  - Elson, D
AU  - Mayer, E
TI  - Novel real-time optical imaging modalities for the detection of neoplastic lesions in urology: a systematic review
J2  - Surg Endosc
PY  - 2019
VL  - 33
SP  - 1349
EP  - 1367
UR  - https://doi.org/10.1007/s00464-018-6578-1
ER  - 
TY  - JOUR
LB  - 95.
AU  - Ikeda, A
AU  - Nosato, H
AU  - Kochi, Y
AU  - Negoro, H
AU  - Kojima, T
AU  - Sakanashi, H
TI  - Cystoscopic imaging for bladder cancer detection based on stepwise organic transfer learning with a pretrained convolutional neural network
J2  - J Endourol
PY  - 2021
VL  - 35
SP  - 1030
EP  - 1035
UR  - https://doi.org/10.1089/end.2020.0919
ER  - 
TY  - JOUR
LB  - 96.
AU  - Tan, WS
AU  - Tan, WP
AU  - Tan, MY
AU  - Khetrapal, P
AU  - Dong, L
AU  - deWinter, P
TI  - Novel urinary biomarkers for the detection of bladder cancer: a systematic review
J2  - Cancer Treat Rev
PY  - 2018
VL  - 69
SP  - 39
EP  - 52
UR  - https://doi.org/10.1016/j.ctrv.2018.05.012
ER  - 
TY  - JOUR
LB  - 97.
AU  - Leitner, CV
AU  - Ederer, IA
AU  - de Martino, M
AU  - Hofbauer, SL
AU  - Lucca, I
AU  - Mbeutcha, A
TI  - Dynamic prognostication using conditional recurrence and progression estimates for patients with nonmuscle invasive bladder cancer
J2  - J Urol
PY  - 2016
VL  - 196
SP  - 46
EP  - 51
UR  - https://doi.org/10.1016/j.juro.2016.01.102
ER  - 
TY  - JOUR
LB  - 98.
AU  - Leo, MC
AU  - McMullen, CK
AU  - O’Keeffe-Rosetti, M
AU  - Weinmann, S
AU  - Garg, T
AU  - Nielsen, ME
TI  - External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system
J2  - Urol Oncol
PY  - 2020
VL  - 38
SP  - 39.e21
EP  - 39.e27
UR  - https://doi.org/10.1016/j.urolonc.2019.10.003
ER  - 
TY  - JOUR
LB  - 99.
AU  - Xylinas, E
AU  - Kent, M
AU  - Kluth, L
AU  - Pycha, A
AU  - Comploj, E
AU  - Svatek, RS
TI  - Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
J2  - Br J Cancer
PY  - 2013
VL  - 109
SP  - 1460
EP  - 1466
UR  - https://doi.org/10.1038/bjc.2013.372
ER  - 
TY  - JOUR
LB  - 100.
AU  - Cambier, S
AU  - Sylvester, RJ
AU  - Collette, L
AU  - Gontero, P
AU  - Brausi, MA
AU  - van Andel, G
TI  - EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette–Guérin
J2  - Eur Urol
PY  - 2016
VL  - 69
SP  - 60
EP  - 69
UR  - https://doi.org/10.1016/j.eururo.2015.06.045
ER  - 
TY  - ELEC
LB  - 101.
AU  - British Association of Urological Surgeons
TI  - BAUS Data & Audit Programme
UR  - www.baus.org.uk/professionals/baus_business/data_audit.aspx
M1  - 14 January 2022
ER  - 
TY  - JOUR
LB  - 102.
AU  - Dindyal, S
AU  - Nitkunan, T
AU  - Bunce, CJ
TI  - The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer
J2  - Photodiagnosis Photodyn Ther
PY  - 2008
VL  - 5
SP  - 153
EP  - 158
UR  - https://doi.org/10.1016/j.pdpdt.2008.05.001
ER  - 
TY  - GEN
LB  - 103.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Narrow Band Imaging for Barrett’s Oesophagus
CY  - London
PB  - NICE
PY  - 2019
UR  - www.nice.org.uk/advice/mib179
Y2  - 11 June 2021
ER  - 
TY  - BOOK
LB  - 104.
AU  - Curtis, L
TI  - Unit Costs of Health and Social Care
CY  - Canterbury
PB  - PSSRU, University of Kent
PY  - 2009
ER  - 
TY  - GEN
LB  - 105.
AU  - National Audit Office
TI  - Out-of-Hours GP Services in England
CY  - London
PB  - National Audit Office
PY  - 2014
UR  - www.nao.org.uk/serarch/out-of-hours/
Y2  - 12 January 2022
ER  - 
TY  - ELEC
LB  - 106.
AU  - HM Revenue and Customs
TI  - Travel – Mileage and Fuel Rates and Allowances
PY  - 2019
UR  - www.gov.uk/government/publications/rates-and-allowances-travel-mileage-and-fuel-allowances/travel-mileage-and-fuel-rates-and-allowances
M1  - 11 June 2021
ER  - 
TY  - GEN
LB  - 107.
AU  - Department of Health and Social Care
TI  - NHS Reference Costs 2009–2010
CY  - London
PB  - Department of Health and Social Care
PY  - 2011
UR  - www.gov.uk/government/publications/nhs-reference-costs-2009-2010
Y2  - 11 June 2021
ER  - 
TY  - GEN
LB  - 108.
AU  - Office for National Statistics (ONS)
TI  - Annual Survey of Hours and Earnings Time Series of Selected Estimates
CY  - Newport
PB  - ONS
PY  - 2020
UR  - www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/datasets/ashe1997to2015selectedestimates
Y2  - 11 June 2021
ER  - 
TY  - RPRT
LB  - 109.
AU  - NHS Pay Review Body
TI  - NHS Pay Review Body Twenty-sixth Report 2012
CY  - London
PB  - The Stationery Office
PY  - 2012
UR  - www.gov.uk/government/publications/nhs-pay-review-body-twenty-sixth-report-2012
Y2  - 11 June 2021
ER  - 
TY  - JOUR
LB  - 110.
AU  - Siebert, U
AU  - Alagoz, O
AU  - Bayoumi, AM
AU  - Jahn, B
AU  - Owens, DK
AU  - Cohen, DJ
AU  - Kuntz, KM
TI  - State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
J2  - Med Decis Making
PY  - 2012
VL  - 32
SP  - 690
EP  - 700
UR  - https://doi.org/10.1177/0272989X12455463
ER  - 
TY  - GEN
LB  - 111.
AU  - Office for National Statistics (ONS)
TI  - National Life Tables, UK: 2016 to 2018
CY  - Newport
PB  - ONS
PY  - 2019
UR  - www.ons.gov.uk/releases/nationallifetablesuk2016to2018
Y2  - June 2021
ER  - 
TY  - GEN
LB  - 112.
AU  - EuroQol Research Foundation
TI  - EQ-5D-3L User Guide, 2018
CY  - Rotterdam
PB  - EuroQol Research Foundation
PY  - 2018
ER  - 
TY  - BOOK
LB  - 113.
AU  - Kaltenthaler, E
AU  - Tappenden, P
AU  - Paisley, S
AU  - Squires, H
TI  - NICE DSU Technical Support Document 13: Identifying and Reviewing Evidence to Inform the Conceptualisation and Population of Cost-effectiveness Models
CY  - Sheffield
PB  - Decision Support Unit, ScHARR, University of Sheffield
PY  - 2011
ER  - 
TY  - BOOK
LB  - 114.
AU  - Gray, AM
AU  - Clarke, PM
AU  - Wolstenholme, J
AU  - Wordsworth, S
TI  - Applied Methods of Cost-Effectiveness Analysis in Healthcare
CY  - Oxford
PB  - Oxford University Press
PY  - 2011
ER  - 
TY  - GEN
LB  - 115.
AU  - Committee for Medicinal Products for Human Use
TI  - Guideline on Adjustment for Baseline Covariates in Clinical Trials
CY  - London
PB  - European Medicines Agency
PY  - 2015
ER  - 
TY  - JOUR
LB  - 116.
AU  - Shen, J
AU  - Hill, S
AU  - Mott, D
AU  - Breckons, M
AU  - Vale, L
AU  - Pickard, R
TI  - Conducting a time trade-off study alongside a clinical trial: a case study and recommendations
J2  - Pharmacoecon Open
PY  - 2019
VL  - 3
SP  - 5
EP  - 20
UR  - https://doi.org/10.1007/s41669-018-0084-1
ER  - 
TY  - JOUR
LB  - 117.
AU  - Dolan, P
AU  - Gudex, C
AU  - Kind, P
AU  - Williams, A
TI  - Valuing health states: a comparison of methods
J2  - J Health Econ
PY  - 1996
VL  - 15
SP  - 209
EP  - 231
UR  - https://doi.org/10.1016/0167-6296(95)00038-0
ER  - 
TY  - JOUR
LB  - 118.
AU  - Gandhi, M
AU  - Rand, K
AU  - Luo, N
TI  - Valuation of health states considered to be worse than death – an analysis of composite time trade-off data from 5 EQ-5D-5L valuation studies
J2  - Value Health
PY  - 2019
VL  - 22
SP  - 370
EP  - 376
UR  - https://doi.org/10.1016/j.jval.2018.10.002
ER  - 
TY  - JOUR
LB  - 119.
AU  - Torrance, GW
TI  - Measurement of health state utilities for economic appraisal: a review
J2  - J Health Econ
PY  - 1986
VL  - 5
SP  - 1
UR  - https://doi.org/10.1016/0167-6296(86)90020-2
ER  - 
TY  - JOUR
LB  - 120.
AU  - Janssen, BM
AU  - Oppe, M
AU  - Versteegh, MM
AU  - Stolk, EA
TI  - Introducing the composite time trade-off: a test of feasibility and face validity
J2  - Eur J Health Econ
PY  - 2013
VL  - 14
IS  - Suppl. 1
SP  - 5
EP  - 13
UR  - https://doi.org/10.1007/s10198-013-0503-2
ER  - 
TY  - BOOK
LB  - 121.
AU  - Gudex, C
TI  - Time Trade-off User Manual: Props and Self-completion Methods
CY  - York
PB  - Centre for Health Economics, University of York
PY  - 1994
ER  - 
TY  - JOUR
LB  - 122.
AU  - Miremami, J
AU  - Kyprianou, N
TI  - The promise of novel molecular markers in bladder cancer
J2  - Int J Mol Sci
PY  - 2014
VL  - 15
SP  - 23897
EP  - 23908
UR  - https://doi.org/10.3390/ijms151223897
ER  - 
TY  - JOUR
LB  - 123.
AU  - The Cancer Genome Atlas Research Network
TI  - Comprehensive molecular characterization of urothelial bladder carcinoma
J2  - Nature
PY  - 2014
VL  - 507
SP  - 315
EP  - 322
UR  - https://doi.org/10.1038/nature12965
ER  - 
TY  - STAT
LB  - 124.
AU  - Great Britain
TI  - Human Tissue Act 2004
CY  - London
PB  - The Stationery Office
PY  - 2004
ER  - 
TY  - ELEC
LB  - 125.
AU  - NHS Health Research Authority
TI  - Hyperthermia for Intermediate risk bladder cancer (HIVEC-II)
UR  - www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/hyperthermia-for-intermediate-risk-bladder-cancerhivec-ii/
M1  - 14 January 2022
ER  - 
TY  - JOUR
LB  - 126.
AU  - Tan, WS
AU  - Feber, A
AU  - Dong, L
AU  - Sarpong, R
AU  - Rezaee, S
AU  - Rodney, S
TI  - DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells
J2  - BMC Cancer
PY  - 2017
VL  - 17
UR  - https://doi.org/10.1186/s12885-017-3758-7
ER  -